scout
|Videos|October 30, 2017

Monitoring MRD in Patients with AML

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in patients with acute myeloid leukemia (AML).

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME